{"id":6135,"date":"2019-10-10T13:39:05","date_gmt":"2019-10-10T08:09:05","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=6135"},"modified":"2025-05-08T11:57:17","modified_gmt":"2025-05-08T06:27:17","slug":"recent-pharma-happenings-for-novartis","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis","title":{"rendered":"First oral GLP-1 treatment approved for type2 Diabetes"},"content":{"rendered":"\n

The US FDA\nhas approved Rybelsus (semaglutide) oral tablets to improve blood sugar in\nadult patients with Type II Diabetes. <\/strong><\/h4>\n\n\n\n

Rybelsus is an oral glucagon-like peptide (GLP-1) receptor protein treatment which has been approved after 15 years of the approval first GLP-1 agonist. GLP-1 is a hormone found in insufficient levels in bodies of type 2 diabetes <\/a>patients.<\/p>\n\n\n\n

GLP-1 drugs are\nnon-insulin treatments which, until now were administered via injection under\nthe skin. Despite their effectiveness in lowering blood sugar level, many\npatients did not opt for them because of the tough and somewhat painful\nadministration method. <\/p>\n\n\n\n

The approval is based on the successful results of the trials being conducted to study the effectiveness of Rybelsus. Moreover, Rybelsus also proved beneficial in slowing down digestion rate, preventing liver from making too much sugar and helping the pancreas to produce more insulin. <\/p>\n\n\n\n

The approval of\nRybelsus was granted to Novo Nordisk.<\/p>\n\n\n\n

Over 30 Million\nAmericans have diabetes with an incidence of on in ten people. And around 95%\nof them are suffering from Type II Diabetes, according to CDC. <\/p>\n\n\n\n

GSK and Lyell\nImmunopharma have announced a joint collaboration to bring next-generation cell\ntherapies to target solid tumours. <\/strong><\/h4>\n\n\n\n

Through the five-year partnership, GSK plans to expand its T-cell receptor therapy pipeline, and work on manufacturing capabilities. The financial terms to date remain concealed. <\/p>\n\n\n\n

Lyell, a\ncellular therapy biotechnology company is focused on advancing functionalities\nof t-cell to target cancers, is going to fortify GSK\u2019s pipeline including\nGSK3377794 that targets the NY-ESO-1 antigen expressed in multiple cancers. <\/p>\n\n\n\n

GSK3377794 is a NY-ESO-1-targeted T cell therapy that GSK licensed from Adaptimmune, is in multiple clinical trials for curing cancers including sarcoma, myeloma, NSCLC, melanoma and ovarian cancer<\/a>.<\/p>\n\n\n\n

Moreover, the\ntherapy has been granted PRIME designation by the European Medicines Agency and\nBreakthrough Therapy Designation by the US Food and Drug Administration.<\/p>\n\n\n\n

Novartis has\ngained the recommendation of the US FDA for its Beovu (brolucizumab) medicine\nto treat wet age-related macular degeneration. <\/strong><\/p>\n\n\n\n

BEOVU is the first FDA-approved anti-VEGF which offers a greater fluid resolution versus aflibercept and helps to maintain eligible wet AMD patients on a three-month dosing interval immediately after a three-month loading phase1 with uncompromised efficacy.<\/p>\n\n\n\n

The approval of\nBEOVU is based on the findings of the clinical trials Phase III HAWK and\nHARRIER. <\/p>\n\n\n\n

Wet-Age Related Macular Degeneration<\/a> (WAMD) also known as Neovascular AMD (NVAMD), is a chronic eye disorder that causes blurred vision or a blind spot in your visual field.<\/p>\n\n\n\n

Furthermore, the\nmost effective treatments for wet AMD involve several anti-angiogenic drugs\nwhich include Lucentis, Avastin, and Eylea. These drugs are injected into the\neye to stop abnormal growth and are the first line treatment for all stages of\nwet macular degeneration. However, none of these treatments provide permanent\ncure, but they can help minimize vision loss.<\/p>\n\n\n\n

Several other\npharmaceuticals are developing therapies for the treatment of patients with\nWet-Age Related Macular Degeneration. Launch of emerging therapies such as\nDE-122 (Tracon pharma), KSI 301 (Kodiak Sciences), BI 836880 (Boehringer\nIngelheim), ONS-5010 (Outlook Therapeutics), RGX-314 (Regenxbio), AKST4290\n(Alkahest) etc. along with other compelling treatment options. <\/p>\n","protected":false},"excerpt":{"rendered":"

The US FDA has approved Rybelsus (semaglutide) oral tablets to improve blood sugar in adult patients with Type II Diabetes. Rybelsus is an oral glucagon-like peptide (GLP-1) receptor protein treatment which has been approved after 15 years of the approval first GLP-1 agonist. GLP-1 is a hormone found in insufficient levels in bodies of type […]<\/p>\n","protected":false},"author":1,"featured_media":6136,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[137,1271,812,704,903,349,639,1183],"industry":[17225],"therapeutic_areas":[17240],"class_list":["post-6135","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-cancer","tag-delveinsight-pharma-news","tag-diabetes","tag-fda","tag-gsk","tag-latest-pharma-news","tag-pharma-news","tag-pharmaceutical-news","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders"],"acf":[],"yoast_head":"\nFDA approves Rybelsus; GSK & Lyell's collaboration; FDA nod to Beovu<\/title>\n<meta name=\"description\" content=\"The US FDA has approved Rybelsus (semaglutide) oral tablets to improve blood sugar in adult patients with Type II Diabetes. \ufeff\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA approves Rybelsus; GSK & Lyell's collaboration; FDA nod to Beovu\" \/>\n<meta property=\"og:description\" content=\"The US FDA has approved Rybelsus (semaglutide) oral tablets to improve blood sugar in adult patients with Type II Diabetes. \ufeff\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-10T08:09:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-08T06:27:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09024341\/News_10.10.2019.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA approves Rybelsus; GSK & Lyell's collaboration; FDA nod to Beovu","description":"The US FDA has approved Rybelsus (semaglutide) oral tablets to improve blood sugar in adult patients with Type II Diabetes. \ufeff","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis","og_locale":"en_US","og_type":"article","og_title":"FDA approves Rybelsus; GSK & Lyell's collaboration; FDA nod to Beovu","og_description":"The US FDA has approved Rybelsus (semaglutide) oral tablets to improve blood sugar in adult patients with Type II Diabetes. \ufeff","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-10-10T08:09:05+00:00","article_modified_time":"2025-05-08T06:27:17+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09024341\/News_10.10.2019.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis","name":"FDA approves Rybelsus; GSK & Lyell's collaboration; FDA nod to Beovu","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09024341\/News_10.10.2019.jpg","datePublished":"2019-10-10T08:09:05+00:00","dateModified":"2025-05-08T06:27:17+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The US FDA has approved Rybelsus (semaglutide) oral tablets to improve blood sugar in adult patients with Type II Diabetes. \ufeff","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novartis#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09024341\/News_10.10.2019.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09024341\/News_10.10.2019.jpg","width":772,"height":482},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09024341\/News_10.10.2019-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">delveinsight pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Diabetes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">GSK<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">pharmaceutical news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">delveinsight pharma news<\/span>","<span class=\"advgb-post-tax-term\">Diabetes<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">GSK<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharmaceutical news<\/span>"]}},"comment_count":"1","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 11 months ago"},"absolute_dates":{"created":"Posted on Oct 10, 2019","modified":"Updated on May 8, 2025"},"absolute_dates_time":{"created":"Posted on Oct 10, 2019 1:39 pm","modified":"Updated on May 8, 2025 11:57 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6135","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=6135"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6135\/revisions"}],"predecessor-version":[{"id":31894,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6135\/revisions\/31894"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/6136"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=6135"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=6135"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=6135"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=6135"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=6135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}